No one is making money on enoxaparin anymore. AMPH admitted on yesterday's CC that is losing money on enoxaparain, but said it would lose even more money if it stopped producing. (I.e., the product produces cash flow that contributes to fixed costs.)
News 
Market Data 
Discover 
